Food and Drug Administration Agency in the USA announces approval of Fibromyalgia drug
Two
world renowned laboratories have announced that a new drug called Savella
(Milnacipran) has been approved by the FDA for the management of Fibromyalgia. Fibromyalgia
(FM or FMS) is a chronic soft tissue disorder characterised by widespread pain
and an increased sensitivity to touch stimuli. Fibromyalgia can occur at any age;
however, it is more common in women between the ages of 20 to 40. Savella is a
selective serotonin and norepeniphrine dual reuptake inhibitor (SSRI). A
serotonin and norepinephrine dual reuptake inhibitor (SSRI) is a type of
antidepressant that reduces the reuptake of serotonin and norepinephrine, in
order to boost their levels in the brain. The approval of Savella comes after
phase III clinical trials involving over 2000 Fibromyalgia patients. Patients taking Savella doses of 100 mg/day and 200 mg/day demonstrated clinically significant
improvements in their global assessment of pain and daily physical function.
The information provided on this website is not intended as specific medical advice and is not a substitute for a professional medical diagnosis or treatment. Read our
Medical Advice Notice.
